Apyx Medical Corporation (APYX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
8.30
↑+51% vs avg
5yr avg: 5.50
30Y Low2.1·High10.0
ROE
↓
-76.9%
-18% vs avg
5yr avg: -64.9%
30Y Low-133%·High117%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High4.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
APYX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Apyx Medical Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $122M | $148M | $56M | $91M | $81M | $440M | $246M | $288M | — | — | — |
| Enterprise Value | $130M | $155M | $63M | $86M | $71M | $410M | $205M | $231M | — | — | — |
| P/E Ratio → | -10.81 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.31 | 2.79 | 1.17 | 1.73 | 1.81 | 9.07 | 8.89 | 10.21 | — | — | — |
| P/B Ratio | 8.30 | 9.95 | 3.92 | 3.37 | 2.14 | 8.15 | 3.86 | 4.04 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
APYX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.94 | 1.31 | 1.63 | 1.60 | 8.44 | 7.40 | 8.17 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
APYX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Apyx Medical Corporation earns an operating margin of -12.2%. Operating margins have expanded from -33.0% to -12.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -76.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.0% | 36.0% | 61.0% | 64.5% | 65.4% | 69.3% | 63.2% | 67.6% | 64.7% | 50.8% | 48.9% |
| Operating Margin | -12.2% | -12.2% | -39.2% | -33.0% | -52.9% | -29.8% | -72.5% | -73.9% | -81.5% | -13.5% | -10.4% |
| Net Profit Margin | -21.2% | -21.2% | -48.8% | -35.7% | -52.1% | -31.3% | -42.9% | -69.8% | 383.6% | -13.0% | -10.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -76.9% | -76.9% | -113.7% | -57.8% | -50.5% | -25.7% | -17.6% | -24.8% | 116.6% | -21.0% | -15.9% |
| ROA | -17.0% | -17.0% | -32.6% | -28.6% | -38.5% | -21.2% | -15.0% | -21.9% | 101.1% | -15.3% | -11.9% |
| ROIC | -22.1% | -22.1% | -65.5% | -51.6% | -68.2% | -47.0% | -83.2% | -36.8% | -23.6% | -26.5% | -19.1% |
| ROCE | -11.8% | -11.8% | -31.2% | -32.4% | -49.4% | -24.0% | -29.2% | -26.0% | -24.1% | -19.2% | -13.3% |
APYX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $8M ($39M total debt minus $32M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.65 | 2.65 | 2.70 | 1.43 | 0.02 | 0.01 | 0.01 | 0.02 | 0.00 | 0.13 | 0.12 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.51 | 0.49 | -0.19 | -0.25 | -0.57 | -0.65 | -0.81 | -0.19 | -0.32 | -0.43 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.15 | -1.15 | -2.95 | -7.59 | -1526.40 | -1481.00 | -420.93 | -2478.50 | -140.26 | -100.75 | -23.59 |
APYX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Apyx Medical Corporation's current ratio of 5.00x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.26x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.52x to 5.00x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.00 | 5.00 | 5.26 | 5.52 | 3.63 | 4.60 | 7.22 | 6.26 | 11.62 | 3.77 | 5.03 |
| Quick Ratio | 4.26 | 4.26 | 4.56 | 4.74 | 2.63 | 4.09 | 6.78 | 5.85 | 10.95 | 2.68 | 3.87 |
| Cash Ratio | 2.71 | 2.71 | 2.96 | 3.43 | 0.86 | 2.34 | 4.58 | 4.80 | 10.15 | 1.67 | 2.74 |
| Asset Turnover | — | 0.79 | 0.74 | 0.66 | 0.86 | 0.71 | 0.37 | 0.33 | 0.17 | 1.25 | 1.04 |
| Inventory Turnover | 3.93 | 3.93 | 2.48 | 1.87 | 1.30 | 2.20 | 2.52 | 1.81 | 1.13 | 2.93 | 3.04 |
| Days Sales Outstanding | — | 115.87 | 117.46 | 97.77 | 149.62 | 159.21 | 228.24 | 119.19 | 111.12 | 45.59 | 47.17 |
APYX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Apyx Medical Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $42M | $36M | $35M | $35M | $34M | $34M | $34M | $34M | $31M | $27M |
Peer Comparison
Compare APYX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 APYXYou | $122M | -10.8 | — | — | 36.0% | -12.2% | -76.9% | -22.1% | — |
 SSKN | $5M | -0.5 | — | — | 56.9% | -27.6% | -114.2% | -38.9% | — |
 ARAY | $58M | -31.7 | 12.7 | — | 32.1% | 1.7% | -2.5% | 3.0% | 12.6 |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AEYE | $95M | -30.6 | — | — | 78.3% | -7.9% | -43.2% | -42.4% | — |
 INMD | $861M | 9.5 | 6.6 | 10.2 | 78.5% | 23.0% | 13.5% | 13.5% | 0.2 |
 LNTH | $6B | 25.3 | 13.8 | 15.8 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 MDT | $99B | 21.5 | 14.3 | 19.2 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 SYK | $112B | 34.8 | 20.2 | 26.1 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 BSX | $83B | 28.9 | 25.1 | 22.8 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 ABT | $150B | 11.3 | 15.7 | 23.6 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See APYX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APYX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APYX vs SSKN
Side-by-side business, growth, and profitability comparison vs STRATA Skin Sciences, Inc..
Start ComparisonAPYX — Frequently Asked Questions
Quick answers to the most common questions about buying APYX stock.
What is Apyx Medical Corporation's P/E ratio?
Apyx Medical Corporation's current P/E ratio is -10.8x. This places it at the 50th percentile of its historical range.
What is Apyx Medical Corporation's ROE?
Apyx Medical Corporation's return on equity (ROE) is -76.9%. The historical average is -13.1%.
Is APYX stock overvalued?
Based on historical data, Apyx Medical Corporation is trading at a P/E of -10.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Apyx Medical Corporation's profit margins?
Apyx Medical Corporation has 36.0% gross margin and -12.2% operating margin.